NCT06699966 is a Phase 4 clinical trial of Celecoxib in Major Depressive Disorder, sponsored by Stony Brook University.

Who is sponsoring NCT06699966?

NCT06699966 is sponsored by Stony Brook University.

What drugs are being tested in NCT06699966?

Interventions in NCT06699966: Celecoxib, Minocycline.

What condition does NCT06699966 study?

NCT06699966 studies Major Depressive Disorder.

Is NCT06699966 still recruiting?

NCT06699966 is currently not yet recruiting. Last updated 21 April 2026.

Last reviewed 2026-04-21 · How we verify

NCT06699966

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stony Brook Medicine Anti-Inflammatory Trial

Not yet recruiting Phase 4 Last updated 21 April 2026

What this trial tests

Phase 4 trial testing Celecoxib in Major Depressive Disorder in 42 participants. Not yet recruiting.

Timeline

1 June 2027

Primary endpoint
1 June 2031

1 January 2032

Quick facts

Lead sponsor	Stony Brook University
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	1 June 2027
Primary completion	1 June 2031
Estimated completion	1 January 2032

Drugs / interventions tested

Celecoxib (celecoxib) — full drug profile →
Minocycline (MINOCYCLINE) — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Stony Brook University

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from Baseline Hamilton Depression Rating Scale (HAM-D 24) Score at 8 Weeks
Time frame: Baseline and 8 weeks.
Participants will have a Hamilton Depression Rating Scale-24 (HDRS) score obtained at baseline. Minimum score 0, maximum possible score 75; the higher the score on the scale, the more severe the degree of depression. After eight weeks of medication treatment, the HDRS score will be reevaluated with the HDRS-24. Participants who have a 50% or greater decrease in their HDRS-24 score will be consider

Sponsor's own description

This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Celecoxib

Trials testing the same drug.

NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting
NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
NCT07150949 — Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MS · Phase 2 · recruiting
NCT07154316 — Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT06997068 — Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest U · Phase 2 · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Stony Brook University trials

Trials by the same sponsor.

NCT07478250 — First Responder Safety Training (FiRST) · NA · not yet recruiting
NCT07076342 — The Role of mGluR5 in CBT-I · Phase 4 · recruiting
NCT07009691 — Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS · NA · recruiting
NCT07114900 — Randomized Controlled Physical Activity App Intervention for Black Women · Phase 3 · active not recruiting
NCT05245227 — Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06699966 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stony Brook University
Last refreshed: 21 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06699966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing